fashion -WSS

fashion

author：comprehensive 2025-10-02 18:50:17 - browse：8152

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Intermittent fasting comes with a heart risk? Not so fast

WSS

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Asbestos, a deadly carcinogen, banned by EPA

Prescription digital therapeutics are key to pharma’s future

Colonoscopy prep: Liquid

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Dexcom's push to bring CGM to type 2 diabetes patients

entertainment

fashion

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

In age of alternative facts, a scholarly course on calling out crap

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

In age of alternative facts, a scholarly course on calling out crap

UpToDate has a racism problem: Dr. Stanley Goldfarb

Bright Health sells Medicare Advantage business to Molina

Use doctors trained outside the U.S. to ease the physician shortage

ChatGPT in medicine: STAT answers readers' burning questions

Being 'nonadherent' patient made me a more empathetic doctor

leisure time

Baby aspirin cuts fat buildup in liver disease patients, in small study

Orchard's therapy for neuron disease in children wins FDA approval

Orchard's therapy for neuron disease in children wins FDA approval

Canadians with cystic fibrosis outlive Americans by a decade

Colonoscopy prep: Liquid

Positive childhood experiences can help future health

hotspot

focus

leisure time

Wikipedia